Macquarie Group Ltd. boosted its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 76.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 131,994 shares of the biopharmaceutical company’s stock after purchasing an additional 57,026 shares during the quarter. Macquarie Group Ltd. owned about 0.06% of Alexion Pharmaceuticals worth $16,060,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Guardian Life Insurance Co. of America boosted its stake in Alexion Pharmaceuticals by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 6 shares during the period. Meeder Asset Management Inc. bought a new stake in Alexion Pharmaceuticals during the 1st quarter valued at approximately $111,000. Fiduciary Trust Co. bought a new stake in Alexion Pharmaceuticals during the 2nd quarter valued at approximately $111,000. Huntington National Bank boosted its stake in Alexion Pharmaceuticals by 1,084.6% during the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 987 shares during the period. Finally, Penserra Capital Management LLC boosted its stake in Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares during the period. Hedge funds and other institutional investors own 94.25% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Position Increased by Macquarie Group Ltd.” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/alexion-pharmaceuticals-inc-alxn-position-increased-by-macquarie-group-ltd/1627948.html.

Several brokerages recently weighed in on ALXN. SunTrust Banks, Inc. restated a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Leerink Swann restated a “buy” rating and set a $182.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. BidaskClub upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 5th. Finally, Royal Bank Of Canada started coverage on Alexion Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $161.00 target price for the company. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $154.56.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 141.46 on Friday. The company’s 50-day moving average price is $142.03 and its 200-day moving average price is $126.93. The firm has a market capitalization of $31.57 billion, a PE ratio of 61.34 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.48. The company had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period in the prior year, the business earned $1.13 earnings per share. Analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.

In other news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now directly owns 5,480 shares in the company, valued at $799,038.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Insiders have sold 17,190 shares of company stock valued at $2,433,669 over the last quarter. Company insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.